Company news
Omeros Corporation (NASDAQ:OMER) news
Omeros Corporation news releases on 6ix. Latest, Jun 9, 2021: Omeros Announces Preliminary Results from Phase 1 Clinical Trial of OMS906
Press releases — page 3
Omeros Announces Preliminary Results from Phase 1 Clinical Trial of OMS906
June 8, 2021
Omeros Announces Preliminary Results from Additional Critically Ill COVID-19 Patients Treated with Narsoplimab
May 27, 2021
Omeros Announces Extension of FDA Review Period for Narsoplimab in HSCT-TMA
May 19, 2021
Omeros Corporation Reports First Quarter 2021 Financial Results
May 9, 2021
Omeros Corporation to Announce First Quarter Financial Results on May 10, 2021
May 4, 2021
Omeros Corporation Announces Approval of ICD-10 Codes for HSCT-TMA Diagnosis and for Narsoplimab Administration
May 3, 2021
Omeros and Quantum Leap Announce First Patients Dosed with Narsoplimab in the I-SPY COVID-19 Trial
March 22, 2021
Omeros Corporation Reports Fourth Quarter and Year-End 2020 Financial Results
February 28, 2021
Omeros Corporation to Announce Fourth Quarter and Year-End Financial Results on March 1, 2021
February 24, 2021
Omeros Hires Nadia Dac as Chief Commercial Officer
January 25, 2021
CMS Confirms Continued Separate Payment for Omeros’ FDA-Approved OMIDRIA® in Ambulatory Surgery Centers
December 2, 2020
Omeros Submits its Biologics License Application to U.S. FDA for Narsoplimab in HSCT-TMA
November 17, 2020
Omeros Corporation Reports Third Quarter 2020 Financial Results
November 8, 2020
Omeros Corporation to Announce Third Quarter Financial Results on November 9, 2020
November 4, 2020
Omeros Reports Final Efficacy and Safety Data from the Narsoplimab Pivotal Trial in HSCT-TMA
October 21, 2020
Omeros Schedules Webcast to Present Final Efficacy Results from Narsoplimab BLA for the Treatment of HSCT-TMA
October 14, 2020
Omeros Provides Update on Separate Payment for OMIDRIA® in the ASCs
September 30, 2020
Omeros’ Investigational New Drug Application for OMS906 Cleared by FDA
August 30, 2020
Omeros Announces Pricing of Public Offerings
August 11, 2020
Omeros Corporation Reports Second Quarter 2020 Financial Results
August 9, 2020
Omeros Corporation Reports Recovery and Survival of All Patients in Study Evaluating Narsoplimab for Treatment of COVID-19-Associated Acute Respiratory Distress Syndrome
August 9, 2020
Omeros Announces Proposed Public Offerings of Common Stock and Convertible Senior Notes
August 9, 2020
Omeros Corporation Announces Presentation of Narsoplimab Pivotal Trial Data at Upcoming European Hematology Association Annual Congress
May 13, 2020
Omeros Corporation Reports First Quarter 2020 Financial Results
May 10, 2020
Omeros Corporation to Announce First Quarter Financial Results on May 11, 2020
May 4, 2020
Omeros Corporation Reports Updated Results from Narsoplimab HSCT-TMA Clinical Trial and Highlights from Recent Clinical and CMC Meetings with FDA
March 1, 2020
Omeros Corporation to Announce Fourth Quarter and Year-End 2019 Financial Results on March 2, 2020
February 23, 2020
Omeros Corporation Appoints Former Amazon Treasurer Kurt Zumwalt to Board of Directors
February 10, 2020
Omeros’ Newly Presented GPR174 Immuno-oncology Data at ESMO Immuno-Oncology Congress Show Inhibition of Both Checkpoint and Tumor-Promoting Factors
December 15, 2019
Omeros Announces Full Exercise and Closing of Underwriter’s Option to Purchase Additional Shares
December 12, 2019
Omeros Announces Pricing of Upsized Public Offering of Common Stock
December 4, 2019
Omeros Reports Positive Data Across Primary and Secondary Endpoints in Pivotal Trial of Hematopoietic Stem Cell Transplant-Associated Thrombotic Microangiopathy Patients Treated with Narsoplimab
December 3, 2019
Omeros Announces Proposed Public Offering of Common Stock
December 3, 2019
Omeros Corporation Reports Third Quarter 2019 Financial Results
November 11, 2019
Omeros to Present GPR174 Data at Upcoming American Association for Cancer Research Conference on Tumor Immunology and Immunotherapy
November 7, 2019
Omeros Scientists Win 2019 Prix Galien Research Award
November 6, 2019
Omeros Corporation to Announce Third Quarter 2019 Financial Results on November 12, 2019
November 5, 2019
Omeros Corporation Announces Publication of Study Results on the Impact of OMIDRIA on Opioid Use and Pain
November 3, 2019
Omeros’ Narsoplimab Receives Positive Opinion from European Medicines Agency for Pediatric Investigation Plan Required for MAA Submission
October 28, 2019
Omeros Corporation Initiates BLA Submission for Narsoplimab for the Treatment of HSCT-TMA
October 27, 2019
Product-Specific J-Code for Omeros’ OMIDRIA® is Now in Effect
September 30, 2019
Omeros Announces Publication of Study Showing that Inhibition of MASP-2, the Key Enzyme of the Complement System’s Lectin Pathway, Protects Against Renal Injury Caused by Proteinuria
September 24, 2019
Omeros Corporation Announces Positive Results from Phase 1 Study of its Lead PDE7 Inhibitor in Development for Addiction
September 15, 2019
FDA Confirms Omeros’ Schedule for Rolling Review of the Company’s BLA for Narsoplimab in the Treatment of HSCT-TMA
September 10, 2019